What happened
Chinese pharmaceutical firms CSPC Pharmaceutical, RemeGen, and Haisco Pharmaceutical Group recently secured significant out-licensing deals, collectively valued over $24.8 billion. CSPC's agreement reached up to $18.5 billion, RemeGen's deal with AbbVie for its RC148 antibody drug was worth up to $5.6 billion, and Haisco granted AbbVie rights to pain drug molecules for up to $745 million. These transactions signal a strategic shift within China's biotech sector, moving from low-cost manufacturing towards high-value innovation, with artificial intelligence reshaping drug discovery.
Why it matters
High-value out-licensing deals, especially AI-driven ones, intensify global competition for novel therapeutics. R&D leaders and procurement teams must reassess pipelines and partnership strategies, recognising China's growing capacity for innovative drug development. Chinese firms use advanced R&D and AI to generate valuable intellectual property, attracting investment from global pharmaceutical giants. This trend indicates future access to early-stage drug candidates will increasingly originate from diverse global sources, demanding agile evaluation and integration capabilities.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
